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Abstract 
Background and Aim: Background: Stem cell transplantation, combined with some bioactive substances, has 
revealed promising outcomes in treating cardiac tissue damage caused by myocardial infarction (MI). In the present 
study, we evaluated the beneficial consequence of mesenchymal stem cells (MSCs) transplantation combined with 
heparin on heart damage within infarcted rabbits. 
Methods: Twenty-eight male New Zealand white rabbits were randomly distributed into four groups: control, MI, 
MI+ MSCs, and MI+MSCs+ heparin. Functional parameters of the left ventricle through echocardiography, lesion 
area through Macro trichrome evaluation, and angiogenesis through Masson's trichrome staining were compared 
between groups.  
Results: Ejection fraction and fractional shortening were improved in MI +MSCs and MI+ MSCs + heparin group 
compared to the MI group (P<0.05). The lesion area was significantly reduced, and angiogenesis was markedly 
increased in MI +MSC + heparin treated animals compared to MI and MI +MSCs groups.   
Conclusion: Although MSCs injection to infarcted area restored normal heart function, we concluded that in the 
infarcted region of animals, MSCs injection combined with exogenous heparin could have more effects on the left 
ventricle functional parameters, cardiac lesions, and new vessel formation. 
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Introduction 
Cardiovascular diseases (CVDs) constitute the main 
cause of global premature deaths and are a prominent 
contributor to decreased quality of life. The World 
Health Organization (WHO) has reported that CVD 
led to approximately 17.8 million deaths worldwide 
in 2017 (1). According to the global burden of 
diseases (GBD), CVDs were responsible for 46% of 
all Iranian deaths (2). CVDs are mentioned to a 
group of disorders such as myocardial infarction 
(MI), heart failure, and several vascular conditions 
that affect the heart and vasculature (3, 4). After 
birth, myocardial cells lose their ability to 
proliferation, and in MI, these cells are loosed and 
replaced with scar tissue, which results in 
irreversible damage to the structure and 
electromechanical function of the heart (5). Despite 
therapeutic approaches in cardiac repair following 
MI, including bypass surgery, the treatment and 
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management remain a major challenge to public 
health. Since both vasculature and myocardial tissue 
are excessively damaged during MI, novel 
therapeutic advances should simultaneously target 
both (5-7). 
The last two decades have dramatically developed 
modern regenerative medicine strategies for cardiac 
regeneration (8-11). Growing evidence shows that 
stem cell-based therapy has emerged as a promising 
strategy to repair damaged myocardial tissue in 
animal models and clinical trials following an acute 
infarction (12-15).  
Various stem cells, including embryonic stem cells 
and adult stem cells, have been studied in heart 
disease and have shown recovering effects. Although 
they act their roles through several mechanisms, cell 
therapy's main objectives are vascularization, 
prevention of cardiomyocyte apoptosis, and 
improved heart electromechanical function (16-18).  
One of the most widely engaged stem cells is 
mesenchymal cells originated from bone marrow. 
These cells can migrate and differentiate into 
different cell types under special circumstances, 
including cardiomyocytes, endothelial cells, and 
smooth muscle cells (19-21).  
Some clinical studies have illustrated that stem cell 
therapy, combined with various bioactive 
compounds, has affirmative impacts in restoring the 
normal structure and function of damaged cardiac 
tissue (22, 23).  
Heparin sulfate is a ubiquitous component of the 
extracellular matrix and basement membrane and has 
a wide range of structures and functions. The heparin 
sulfate chain has been shown to participate in 
angiogenesis's biological processes (24-27). 
Heparin-binding vascular endothelial growth factor 
(VEGF) cooperates in angiogenesis prompted by 
hypoxia, inflammation, and tumor growth. Studies 
have also shown that heparin administration during 
left ventricular hypertension increases fibroblast 
growth factor (FGF)2 and VEGF in the left ventricle 
and increases blood flow capacity and capillary 
density (28-30).  
In line with the studies, we decided to use heparin 
family drugs to increase the angiogenic capacity of 
bone marrow MSCs in MI treatment. 
Methods 
Animal model 
This investigation follows the "Guide for the Care 
and Use of Laboratory Animals," published by the 
United States National Institutes of Health (NIH 
Publication, 8th Edition, 2011). All human sample 
collections, animal care, and experimental protocols 
handled in this study were under ethical permissions 
approved by the Iran University of Medical Sciences' 
ethical committee. In this study, twenty-eight New 
Zealand white rabbits with a weight ranging from 
2500 to 3000 g were purchased from Razi Vaccine 
and Serum Research Institute. All animals were 
housed in controlled temperature conditions (22±2◦C) 
and 12 hours' dark-light cycles. Animals had free 
access to standard laboratory feed temperature 
conditions randomly distributed into four groups, 
with seven animals in each group. 
1) control group (normal rabbits): 150 μl culture 
media were injected into animals intramyocardially. 
2) MI-induced rabbits: MI was induced, and animals 
did not receive any injection.  
3) MI+MSCs group: 150 μl MSCs were injected 
intramyocardially into the infarcted area. 
4) MI+MSCs + heparin group: 150 μl MSCs were 
injected intramyocardially into the infarcted area, 
followed by subcutaneous heparin injection (200 
U/Kg for 28 days). 
Induction of MI 
Animals were anesthetized with 35 mg/kg ketamine 
and 5 mg/ kg xylazine intramuscularly. Under the 
sterile condition, a left intercostal thoracotomy was 
performed between two and three intercostal spaces. 
Then, the left anterior descending (LAD) was ligated 
between the first and second diagonal branches of the 
coronary artery with a 6.0 chromic suture. Following 
coronary blood flow occlusion, a pale color in the 
distal myocardium was observed after ligation. This 
color change confirmed that a heart attack has 
occurred.  
Human mesenchymal stem cell (hMSCs) isolation 
and culture  
Human bone marrow samples were obtained from 
Shariati Hospital (Tehran University of Medical 
Sciences, Iran). The cells were cultured and grown in 
a culture medium with 20% fetal bovine serum 
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(FBS) and 1% penicillin + streptomycin and 
incubated in an incubator at 37 0C with 5% CO2. 
After 24 hours, the mesenchymal cells adhered to the 
bottom of the flasks. After 60% of confluency, 
adhered cells were trypsinized and harvested for 
subculture. 150 μl of cell culture medium containing 
106 MSCs cells was injected intramyocardially to 
rabbits' infarcted area in MSCs and MSCs + heparin 
groups. 
 
Flow cytometry assay 
After 80% confluency, human MSCs were 
trypsinized and detached from flasks, centrifuged (at 
900 ×g for 7 min). The pellets were resuspended in 
500 μl of PBS and incubated with appropriate 
antibodies (1 hour in the dark) for reading with a 
flow cytometer (Partec, Germany). The applied 
MSC-specific antibodies were included anti-CD105, 
anti-CD90, anti-166. Also, anti-CD44 and anti-
CD45, and anti-CD34 were used as negative 
markers.  
Measurement of the left ventricle (LV) functional 
activity  
Functional parameters of LV, including ejection 
fraction (EF), Left-ventricular end-diastolic 
dimension (LVEDD), and fraction shortening (FS), 
were analyzed by echocardiography. 
Histological evaluation 
The isolated heart tissues were kept in 4% 
formaldehyde solution for seven days. Then the 
paraffin block is prepared according to the protocol 
by Tissue Processor. Tissue sections were made with 
a microtome, 7 microns thick, and were placed on a 
slide. For Masson's trichrome staining, the prepared 
slides were stained with Masson's trichrome for 
angiogenesis evaluation.  
Statistical analysis 
All results were analyzed using the SPSS version 
15.0 (SPSS Inc. Chicago, IL, USA). ANOVA test 
and Tukey (post hoc) were performed to compare 
case results with the control group. Kruskal-Wallis 
and Mann-Whitney tests were used to compare 
MSCs+heparin results with MSCs results. All study 
data were displayed as mean ± standard deviation 
(SD), and P<0.05 was used as statistically 
significant.  
Results 
Bone marrow MSCs were firstly prepared and 
cultured (Figure 1). After obtaining the MSCs, heart 
surgery was implemented to create a MI model in 
rabbits, and 150 µl cultured cells followed with 
heparin (200 U/Kg) were used for treatment. 
Flow cytometry finding 
For the characterization of MSCs extracted from 
bone marrow, we employ a flow cytometry 
technique to investigate specific markers of 
mesenchymal cells compared to hematopoietic cells. 
The flow cytometric findings displayed that many 
cultured cell amounts expressed mesenchymal 
markers, including CD105 (99.5%), CD90 (98.8%), 
CD44 (96.8%), and CD166 (93%). In contrast, 
hematopoietic markers' expression rate, including 
CD45 and CD34, was 3.8% and 2.8%, respectively. 
These results confirm MSCs quality and 
hematopoietic cell removal after MSCs isolation 
from bone marrow (Figure 2). 
Effect of heparin and MSCs on hemodynamic 
parameters 
FS, EF, and LVEDD were compared after induction 
of MI and at 4 and 8 weeks after treatment (Table 1). 
After MI, LVEDD did not change between groups. 
The difference between any of the groups was not 
significant. (Table 1). MSCs transplantation 
significantly improved the EF and FS in 4 and 8 
weeks after treatment. All these beneficial impacts of 
MSCs were significantly increased in combination 
with heparin injection. 
Histological analysis 
Angiogenesis in the heart tissue was measured 8 
weeks after treatment by Masson's trichrome 
staining. These findings revealed that angiogenesis 
was significantly higher in MI+MSCs and 
MI+MSCs+heparin-treated rabbits than MI group. 
The histological evaluation also showed that the 
amount of angiogenesis was significantly higher in 
MI+MSCs+heparin than in the MI+MSCs group 
(Figure 3). Angiogenesis was measured in a unit of 
surface (µm2). The mean number of counted new 
vessels in the MI group and MSCs and 
MSCs+heparin receiving groups were 5.8±0.67, 
19.6±1.34, and 26±0.71, respectively (Figure 4). 
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Macro-trichrome studies for measuring the 
lesion's level 
Macro-trichrome studies were examined under a 
microscope using white light. Lesion levels were 
assessed in the study groups. The lesion level in the 
macro-trichrome study in the studied groups showed 
that the MI group's lesion level was significantly 
different from MSCs and MSC+heparin groups. The 
lesion level in the sham group and MSCs and 
MSCs+heparin groups was 25047.2±911.42, 
14509.4±588.08, 11065.6 ± 756.68, respectively. 
 
 
Figure 1. (A) Bone marrow stem cells. (B) Human 
bone marrow-derived cells in the fifth passage. 
 
Figure 2. Flow cytometry diagram of A) CD90, B) 
CD105, C) CD166, and CD44 mesenchymal antibodies 
and E) CD45 and CD CD34 hematopoietic antibodies. 
 
Figure 3. Comparison and evaluation of angiogenesis 
in the study groups by using Mason's trichrome staining 
after 8th week. (A) Fibrous tissue of the heart after 
ischemia. (B) Angiogenesis is well seen in the BMSC-
treated group. (C) Angiogenesis is seen in the BMSC + 
heparin group. Yellow arrow: collagen; blue arrow: 
fibrous tissue; red arrow: mature blood cells; green 
arrow: blood vessel. 
 
 
Figure 4. Comparison of angiogenesis in Masson's 
trichrome staining. *Significant differences with the MI 
group, #significant difference between MSC group and 
MSC + heparin. MSC: mesenchymal stem cell.  
 
 
Figure 5. Comparison of lesion levels in macro-
trichrome evaluation. *Significant differences with the 
MI group, # significant difference between MSC group 
and MSC+heparin. MSC: mesenchymal stem cell. 
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Table 1. Comparisons of cardiac functional parameters between study groups. 
 Control MI MSCs MSCs + heparin p-value 
EF% 
After MI 69.05 ± 0.012 48.1 ± 0.01 53.2 ± 0.09 52 ± 0.016 < 0.05 
4 weeks 69.85 ± 0.09 49.89 ± 0.014 55 ± 0.05 54.9 ± 0.06 < 0.05 
8 weeks 71.02 ± 0.012 45.9 ± 0.03 55.6 ±0.04 55.3 ± 0.015 < 0.05 
FS 
After MI 44.23 ± 0.14 20.02 ± 0.001 25.23 ± 0.02 28.24 ± 0.03 < 0.05 
4 weeks 43.23 ± 0.07 22.09 ± 0.032 23.04 ± 0.04 26.12 ± 0.08 < 0.05 
8 weeks 43.86 ± 0.85 23.95 ± 0.04 27.4 ± 0.41 30.01 ± 0.07 < 0.05 
LVEDD 
After MI 13.36 ± 0.01 12.1 ± 0.12 11.9 ± 0.03 11.6 ± 0.31 ˃ 0.05 
4 weeks 14.23 ± 0.14 13.8 ± 0.15 12 ± 0.09 12.1 ± 0.01 ˃ 0.05 
8 weeks 13.36 ± 0.45 12.4 ± 0.02 13.8 ± 0.01 12.4 ± 0.25 ˃ 0.05 
Comparisons of cardiac functional parameters were evaluated by echocardiography between study groups after MI 
induction and at 4 and 8 weeks after treatment. A one-way ANOVA test was applied for data analysis. All results were 
presented as mean ± standard deviation (SD), and P<0.05 was considered statistically significant. Abbreviations: 
LVEDD: Left Ventricle End Diastolic Dimension, FS: fractional shortening, EF: ejection fraction, MI: myocardial 
infarction, MSCs: mesenchymal stem cells.
Discussion 
In this study, MI was induced in a rabbit model, 
and then the effect of MSC infusion alone and with 
heparin on hemodynamic and histological 
parameters was investigated. Heparin significantly 
improved the beneficial effect of MSCs on 
angiogenesis induction and hemodynamic 
parameters improvement after MI. 
Several studies have represented the beneficial 
impacts of originated-bone marrow MSCs therapy 
in MI, neurological, and kidney disorders (31-34). 
The susceptibility of MSCs to regenerate cardiac 
damage following ischemic myocardium in 
animal and clinical results is a step forward in 
ameliorating cardiac cell therapy as a relevant 
therapeutic approach. Further investigations will 
most likely have required to find more practical 
strategies to augment and facilitate stem cell 
impacts on myocardial regeneration (35-37). Most 
clinical trials have shown that 4 to 6 months after 
stem cell transplantation, LVEF increases about 7 
to 9 percent, systolic end volume decreases, blood 
flow and angiogenesis improve in the infarcted 
area (11, 38-40). In a clinical investigation, Peter 
Dandruff and his colleagues showed that patients 
who underwent coronary artery bypass graft 
(CABG) surgery with MSCs injection had a better 
ventricular ejection index or EF than patients who 
had only extracellular bypass surgery without stem 
cell therapy (41). The present study results 
indicated that bone marrow MSCs transplantation 
for cardiac repair improved EF and FS in infarcted 
rabbits, in agreement with previous studies.  
Bone marrow MSCs possess a high potential for 
regeneration of cardiac performance since 
engrafted MSCs secrete different biological 
factors, including platelet-derived growth factor 
(PDGF), stem cell-derived factor (SDF), VEGF, 
and matrix metalloproteinase (MMPs) in a 
paracrine manner. These factors contribute to 
angiogenesis induction, extracellular matrix 
remodeling, and stem cell recruitment (42, 43). 
The paracrine secretion of VEGF, a proangiogenic 
factor, promotes angiogenesis induction and 
vascular regeneration and also impairs the 
apoptotic pathway (44, 45). Tang YL et al. 
reported that cardiac performance improvement in 
MSCs therapy might be related to the self-renewal 
capacity of transplanted MSCs that can retain 
angiogenesis and cardiomyocyte recovery through 
VEGF protein secretion (14, 46). Our previous 
finding showed that heparin, combined with 
MSCs therapy, improves stem cells' actions in the 
VEGF secretion and cardiac tissue restoration 
after infarction (47). Heparin is an anticoagulant 
factor and can bind to VEGF and finally enhance 
this angiogenic factor's affinity to its receptor (48). 
So, it seems that heparin is a beneficial option to 
increase the effect of stem cell transplantation for 
angiogenesis induction and cardiac tissue 
regeneration. The combination of exogenous 
heparin with MSCs transplantation therapy into an 
infarcted rabbit model was investigated in the 
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current study. The histological analysis confirmed 
that new vessel formation was increased in the 
ventricular myocardium of animals who received 
MSCs + heparin compared to MSCs alone. 
Histological evaluations also highlighted 
increased angiogenesis amount and decreased 
lesion area in the MSCs group compared to MI and 
in the MSCs+ heparin group compared to MSCs 
alone. According to previous studies, the recovery 
velocity of the injured myocardium can be 
influenced by the MSCs differentiation into 
myocardiocytes, increased angiogenesis in the 
damaged heart tissue, and paracrine secretion of 
growth factors led to increased tissue repair at the 
injury area. 
Conclusion 
Overall, these data demonstrated that MSCs therapy 
combined with exogenous heparin administration 
could induce angiogenesis and reduce the lesion area 
after cardiac injury. Although this study examined 
the combined effects of MSCs and heparin on 
hemodynamic parameters and angiogenesis, it did 
not address other MSCs and heparin effects on 
damaged heart tissue. Therefore, in later studies, it is 
recommended that other functional aspects of MSCs 
and heparin be investigated to improve infected 
tissue.  
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